TrialMultiple sclerosis (Houndmills, Basingstoke, England)2022

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.

Mary Rensel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.